The effect of (1-->3)-beta-D-glucans, carboxymethylglucan and schizophyllan on human leukocytes in vitro.
(1-->3)-beta-D-glucans are known as potent inductors of humoral and cell-mediated immunity in humans and animals. (1-->3)-beta-D-glucans isolated from various sources differ in their chemical structure and physical parameters and consequently in their immunomodulatory potential. In this study the immunomodulatory activity of two (1-->3)-beta-D-glucans schizophyllan (SPG) and carboxymethylglucan (CMG) was determined and compared on human blood leukocytes in vitro. Both SPG and CMG activated blood phagocytes and lymphocytes as demonstrated by increased whole blood production of reactive oxygen species, by increased production of pro-inflammatory cytokines IL-6, IL-8, and TNF-alpha, by increased surface expression of CD69 on lymphocytes, and by altered expression of CD11b and CD62L on polymorphonuclear leukocytes and monocytes. SPG demonstrated a significantly higher potential to stimulate blood phagocytes and production of selected pro-inflammatory cytokines than CMG. The higher potency of SPG to stimulate human blood phagocytes in vitro could be caused by factors such as higher branching frequencies or neutral polymer charge of SPG or different conformation in solution if compared with CMG.
Kubala
Lukas
L
Institute of Biophysics Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic.
Ruzickova
Jana
J
Nickova
Kristina
K
Sandula
Jozef
J
Ciz
Milan
M
Lojek
Antonin
A
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D039481:CD11b Antigen / Q000378:metabolism; D005434:Flow Cytometry; D005936:Glucans / Q000494:pharmacology*; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D019041:L-Selectin / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D008163:Luminescent Measurements; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010586:Phagocytes / Q000187:drug effects / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D012566:Sizofiran / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D047071:beta-Glucans
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D039481:CD11b Antigen; D005936:Glucans; D015850:Interleukin-6; D016209:Interleukin-8; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D047071:beta-Glucans; D019041:L-Selectin; C016658:phorbolol myristate acetate; D009240:N-Formylmethionine Leucyl-Phenylalanine; C029933:carboxymethyl-beta-1,3-glucan; D012566:Sizofiran; C033363:beta-1,3-glucan; D013755:Tetradecanoylphorbol Acetate